OUR IMPACT


Making a real difference.

We are creating a world in which everyone can access tools for protecting against disease and leading a healthy life.

ONE PLANET, ONE PEOPLE

Disease Knows No Borders

AAHI innovates and optimizes its platforms to support vaccines that not only provide robust protection, but also can easily be made available in low-resource ares most burdened by disease. Our scientists take a pragmatic and creative approach, to develop cost-effective and sustainable solutions to prevent and treat disease all around the world.

Help support the development of accessible vaccines and immunotherapies for underserved communities by donating today!

Local Self-Reliance

Enabling rapid local response to infectious disease threats by transferring manufacturing technology and know-how to local vaccine manufacturers.
We transfer adjuvant formulation and manufacturing know-how to strengthen local development and production capabilities.
PRIORITIZING ACCESS

Solutions for Infectious Diseases

AAHI is working to establish resilient global vaccine infrastructure through sustainable supply chain solutions that ease access to protection against disease in low-resource areas of the world. 

Many infectious diseases that run rampant in low-and middle-income countries are treatable, yet inaccessible. AAHI aims to alleviate the burden of such diseases and to break the cycle of poverty.
DEVELOPING PROTECTION AGAINST

Viruses

Protect Against COVID-19 COMING SOON. BACK TO OUR IMPACT

Protect Against HIV COMING SOON. BACK TO OUR IMPACT

Protect Against Yellow Fever COMING SOON. BACK TO OUR

Protect Against Influenza AAHI: Is developing an inhalable RNA vaccine candidate

DEVELOPING PROTECTION AGAINST

Parasites

Protect Against Amebiasis AAHI: Is developing the first vaccine against amebiasis, a disease caused by a parasite called Entamoeba

Protect Against Malaria AAHI: Supports the development of eight different malaria vaccine candidates using our immune-enhancing adjuvant formulations

Protect Against Hookworm AAHI: Supports the development of a hookworm vaccine candidate, currently in Phase 2 human clinical

Protect Against Chagas AAHI: Supports the development of innovative vaccine candidates by licensing recombinant proteins and it's GLA-SE

Protect Against Leishmaniasis AAHI: Developed a diagnostic test for visceral leishmaniasis (VL) that spares patients painful and potentially

DEVELOPING PROTECTION AGAINST

Bacteria 

Protect Against Tuberculosis AAHI: Developed a safe and immunogenic tuberculosis (TB) vaccine candidate that elicits robust immune responses in adults, in a

Protect Against Leprosy AAHI: Developed an adjuvanted leprosy vaccine candidate, LepVax, proven to be safe and immunogenic in a phase 1 clinical trials.

DEVELOPING PROTECTION AGAINST

Snake Bite

Protect Against Snake BitesAAHI: Collaborates with the Instituto Clodomiro Picado of University of Costa Rica